Imaging DNA damage allows detection of preneoplasia in the BALB-neuT model of breast cancer.
INTRODUCTION
The DNA damage response (DDR) is a highly regulated cellular process that follows exposure to ionizing radiation (IR) and other genotoxic insults (1). The DDR is activated during the earliest stages of cancer development, when it is triggered by the onset of oncogenic stress.
Signaling via the ATM-Chk2-p53 DDR pathway minimizes genomic instability and inhibits cell cycle progression and tumor formation (2) . This protective mechanism is eventually overridden, possibly precipitated by mutations of the p53 gene (3) . Early reports of DDR activation during bladder, colon, breast, skin and lung cancer development showed that it was accompanied by the activation of signaling proteins downstream of pATM, including pChk2 and γ H2AX (4, 5) . DDR activation has since been observed to occur during the development of many other types of cancer including pancreatic (6) , ovarian (7) and hepatocellular carcinomas (8) . Given the near ubiquitous nature of DDR activation during oncogenesis, it has been suggested that markers of DNA replication stress and constitutive DDR activation might distinguish neoplastic growth from normal tissues. This has been substantiated by immunohistochemical analyses of human tissues.
In one study markers of DDR activation were observed only in sub-populations of lymphocytic cells in bone marrow, spermatocytes in adult testes and basal esophageal cells (4) . This raises the possibility that detection of DDR activation in vivo could allow early detection of precancerous and cancerous lesions (9) .
It has been shown previously that an anti-γH2AX antibody-based imaging probe can detect γ H2AX non-invasively (10) . Anti-γH2AX antibodies were modified by the addition of the HIV-1 transactivator of transcription protein-derived cell-penetrating peptide, TAT, which harbors a nonclassical nuclear localization sequence, promoting nuclear translocation of the conjugate. Anti-γ H2AX-TAT was radiolabeled with indium-111 ( 111 In), to allow SPECT imaging. Following induction of γ H2AX by X-irradiation or bleomycin, 111 In-anti-γH2AX-TAT accumulated in human breast cancer xenografts in athymic mice, and the extent of 111 In uptake was linearly dependent on the level of γ H2AX expression (10) .
In this report the ability of the 111 In-anti-γH2AX-TAT probe to detect DDR during tumorigenesis was investigated using a transgenic mouse model of breast cancer in which the mouse mammary tumor virus (MMTV) promoter drives neuT expression. NeuT, a variant of the rat neu HER2-homolog, contains a point mutation in the transmembrane region and is highly tumorigenic compared to wild-type (WT) neu or human HER2 (11) . When BALB-neuT mice reach 21-28 days of age, the neuT protein is over-expressed in mammary glands and areas of atypical hyperplasia start to form (12) . These progress to in situ carcinomas at about day 60 and to invasive cancers by day 120-150. Neoplastic change occurs, albeit asynchronously, in all mammary glands so that by about 120 days one or more tumors are palpable and by about day 230 (33 weeks) all 10 mammary glands contain palpable tumors (13) . In this study we explored the ability of 111 In-anti-γH2AX-TAT SPECT imaging to detect tumors during oncogenesis in BALB-neuT mice.
MATERIALS AND METHODS

Animal Model
All animal procedures were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and with local ethical committee approval. Female WT BALB/c mice (Charles River, Wilmington, MA, USA) were crossed with male BALB-neuT mice (gift from Guido Forni). The BALB-neuT strain originated from a transgenic CD1 random-bred breeder male mouse carrying the mutated rat neuT oncogene driven by the MMTV promoter (1). The mutated gene encodes a single point mutation that replaces the valine residue at position 664 in the transmembrane (TM) domain of p185/neu with glutamic acid. This mutation promotes p185
homo-and heterodimerization and transforms the neu protooncogene into a dominant transforming oncogene. Offspring of the BALB-neuT male and WT female cross were genotyped using the following primers: 5'-CGCACGTCCTCCAGGTAG-3' and 5'-GATTCCAACGACCACCACTA-3'. NeuT-positive female mice were used for experiments.
Immunohistochemistry
At selected time points, mammary tissue or mammary tumors were harvested from female BALB/c or BALB-neuT mice. Flash frozen tissues were embedded in OCT and 10 μ m sections were prepared. Tissue sections were stained with haematoxylin/eosin and images were acquired using a wide-field microscope. Alternatively, sections were washed to remove OCT, fixed (4% PFA, 10 min, room temperature), permeabilized (1% triton X-100 in PBS, 10 min, room temperature), blocked (1% BSA in PBS, 1 h, 37 °C), and incubated with anti-γH2AX
antibodies raised in mouse (Calbiochem, Millipore, Watford, UK; 1:800 in blocking buffer, 1 h, (AUC), first uptake moment) on a voxel-per-voxel basis were extracted for the whole tumour using Matlab, and parametric images generated. Images were inspected, and where tumors larger than 3x3 voxels was found, mice were scored as positive.
Statistical Methods
All data and graphs are expressed as mean ± one standard deviation, unless defined otherwise. Differences in the number of γH2AX foci/cell were assessed using an ANOVA test.
Differences in the uptake of 111 In-anti-γH2AX-TAT and 111 In-rIgG-TAT were assessed by fitting a multilevel linear model with age, compound and set (data were obtained in two independent sets of n = 20 and n = 12) as explanatory variables. An interaction between age and compound was fitted to allow different effects of age for each compound. The uptake of 111 In-anti-γH2AX-TAT and 111 In-rIgG-TAT in mice of each age group was compared by fitting a multilevel linear model.
Age groups were chosen based on known timing of development of mammary fat pad lesions in the BALB-neuT model. As a sensitivity analysis, 'nil' measurements, where no VOI could be drawn, since no signal/structure was discernable, were excluded and the models were fitted again, but this variation did not alter the conclusion. Times to tumor detection by SPECT, MRI
RESULTS
DDR Activation During Carcinogenesis in BALB-neuT Mice
Histological examination of mammary fat pads from BALB-neuT mice confirmed the progressive development of atypical hyperplasia and in situ lesions, leading to invasive carcinoma by the age of 100-130 days (Fig. 1A) . In-anti-γH2AX-TAT uptake often exceeded 5%ID/g, whereas in only one case did the uptake of the control probe marginally exceed 5%ID/g. Additionally, analysis of data on individual lesions showed that all lesions that became palpable during the study had been identified by SPECT imaging before becoming detectable by palpation. In 14 out of 16 mice, the first lesion to be detected by 111 In-anti-γH2AX-TAT SPECT imaging was subsequently also the first lesion to become palpable. 111 In-anti-γH2AX-TAT was administered to young or old BALB/c WT mice and following acquisition of SPECT images performed at 24 h followed by retrieval of tissues for radioactivity counting ( Supplementary Fig. S3 ). Uptake of 111 In-anti-γH2AX-TAT was slightly higher in the mammary fat pads of young versus old mice: however, this did not reach statistical significance (mean +/-SD: 2.28±0.35 versus 1.21±0.49; P=0.10). The level of uptake in the mammary fat pads in BALB/c WT mice was therefore well below the 5%ID/g cut-off that was used to denote positive 111 In-anti-γH2AX-TAT uptake in BALB-neuT mice.
Lack of Effect of 111 In-RICs on γH2AX Expression and Tumor Growth
To evaluate the possibility that administration of 111 In-anti-γH2AX-TAT or 111 In-rIgG-TAT could itself affect tumor development, the tumor-free survival of mice that had undergone repeated imaging was compared to that of control animals. No significant differences were detected (log rank test; P=0.41) (Fig. 4) . Similarly, in a group of animals aged 89-96 days there was no statistical difference in the number of 
Early Detection of Precancerous Lesions
Small tumors were not identified in CT images, acquired to provide an anatomical reference for SPECT images (results not shown). However, tumors with a diameter as small as 1.26 mm were visualized using T1-weighed MRI images and were particularly clearly identifiable in AUC-parameter maps generated after DCE-MRI (Fig. 5A ). The median age at which tumors were detectable by DCE-MRI and palpation was 120 and 131 days, respectively (P=0.10). SPECT imaging using 111 In-anti-γH2AX-TAT was superior to DCE-MRI (P=0.058), with median age at detection of first tumor of 96 days (Fig. 5B) .
DISCUSSION
Oncogenic stimulation leading to DNA replication stress occurs early in the development of cancer. The resulting accumulation of DNA damage triggers constitutive activation of the DDR, typified by expression of phosphorylated forms of key DNA repair proteins including pATM (S1981), γ H2AX (S139) and pChk2 (Thr68) (3, 5, 9, 15, 16) . As a result of DDR activation, DNA damage is repaired and its detrimental effects, including genomic instability, avoided. However, unrelieved oncogenic stress eventually results in a breach of this protective mechanism with subsequent progression to the malignant phenotype. A large body of published evidence has shown that DDR is activated during development of many tumor types (17) . Several reports have shown immunohistochemical evidence that DDR proteins are highly expressed in precancerous lesions but less so in invasive cancers or corresponding normal tissues (4) (5) (6) (7) (8) . It is therefore logical to explore these molecules as biomarkers of early cancer development and reasonable to hypothesize that visualization of components of the DDR might provide an excellent means of early cancer detection (9) . It was shown previously that it is possible to image DNA damage using the prototypic SPECT imaging tracer, 111 In-anti-γH2AX-TAT (10). We have used the same probe to test the hypothesis that DDR imaging can detect premalignant lesions in the BALB-neuT breast cancer model.
Expression of
γ H2AX was significantly increased in hyperplastic and DCIS lesions in mice aged between 76 and 106 days compared to normal mammary fat pads (from young mice) and mature tumors (from older mice) (Fig. 1B) . pATM, the kinase primarily responsible for H2AX phosphorylation to form γH2AX, was also upregulated during this period, while total ATM remained unchanged. In contrast to this robust activation of the DDR in BALB-neuT- In-rIgG-TAT had no effect on tumor-free survival of animals (Fig. 4) . 111 In-anti-γH2AX-TAT SPECT imaging of the DDR was superior to anatomical imaging methods. CT, acquired as anatomical reference during SPECT, provided images with poor softtissue contrast such that only tumors >5 mm in diameter were detectable. T1-weighed MRI imaging and DCE-MRI imaging provided better contrast. However, the average age of mice when tumors first became detectable by DCE-MRI was 120 days, significantly later than detection by DDR-imaging using SPECT i.e. 96 days.
The data presented in Figure 3 , show that uptake of both 111 In-anti-γH2AX-TAT and the non-specific probe is higher in carcinomas in older mice compared to intermediate-aged mice. This raises the question as to how the extent of uptake ofroutinely combined with an anatomical imaging modality such as CT or MRI it is predicted that larger, late-stage lesions (i.e. the human equivalent of the mature cancers seen in mice > 106 days old) would be detected by correlative anatomical imaging.
However, earlier stage lesions would be predicted to be positive for 111 In-anti-γH2AX-TAT uptake but lack CT/MRI evidence of a mass lesion. Thus it may be possible to distinguish between early and late stage lesions.
These results provide proof-of-principle that it is possible to image 
